Amyloid Cascade into Clarity
- PMID: 27760336
- DOI: 10.1016/j.immuni.2016.10.006
Amyloid Cascade into Clarity
Abstract
In a recent issue of Nature, Sevigny et al. (2016) report findings from a phase 1b clinical trial of aducanumab (a monoclonal antibody targeting misfolded amyloid-β peptides), revitalizing the "amyloid cascade hypothesis" and bringing mononuclear phagocytes center stage in the treatment of Alzheimer's disease.
Copyright © 2016 Elsevier Inc. All rights reserved.
Comment on
-
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323. Nature. 2016. Update in: Nature. 2017 Jun 21;546(7659):564. doi: 10.1038/nature22809. PMID: 27582220 Updated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
